Skip to main content

Table 2 Progression of vitreous hemorrhage score during the study in Group A

From: Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial

Group A Baseline After 1st IVB (8 Weeks) After 2nd IVB (16 Weeks) After 3rd IVB (24 Weeks)
Grade 0 0 2 8 21
Grade 1 3 6 17 8
Grade 2 14 18 7 4
Grade 3 18 9 3 2
  1. IVB intravitreous bevacizumab injection